Christopher Kersey PhotoChristopher W. Kersey
Partner and Managing Member
Camden Partners

Christopher W. Kersey is a Partner and Managing Member of Camden Partners in Baltimore, Maryland, where he focuses on private equity investments in the health care and business services industries.

Dr. Kersey serves on the board of directors of Community Education Centers (CEC) Inc., Essence Group Holdings Corporation, Implantable Provider Group (IPG) Inc., Lumeris Corporation, Metabolon Inc., PatientSafe Solutions Inc., Santa Rosa Holdings Corporation and Scribes STAT Inc. Dr. Kersey’s previous portfolio companies include MedServe Inc. (acquired by Stericycle Corporation, NASDAQ: SRCL), AlgoRx Pharmaceuticals Inc. (acquired by Anesiva Corporation, NASDAQ: ANSV), LipoScience Corporation (NASDAQ: LPDX), MacroGenics Corporation (NASDAQ: MGNX), Medivance Inc. (acquired by C.R. Bard Corporation, NYSE: BCR), Pet DRx Inc. (acquired by VCA Antech Corporation, NASDAQ: WOOF), Rejuvenon Inc. (acquired by Helsinn Healthcare S.A.), Targacept Corporation (NASDAQ: TRGT), Webmedx Inc. (acquired by Nuance Communications, NASDAQ: NUAN) and Xeotron Corporation (acquired by Life TechnologiesCorporation, NASDAQ: LIFE).

Dr. Kersey serves as the Chairman of the Board of Johns Hopkins Medicine International, the global development arm of Johns Hopkins Medicine with hospital management and clinical education services in the Middle East, North America, South America, Europe and Asia. Dr. Kersey serves on the board of trustees of Johns Hopkins Medicine and the board of trustees of The Johns Hopkins Hospital, the #1 ranked hospital in the country, according to the U.S. News & World Report annual rankings of American hospitals. Dr. Kersey serves on the board of directors of The Johns Hopkins Hospital Endowment Fund, and he is a member of the Johns Hopkins Medicine Compensation Committee and the Johns Hopkins Medicine Patient Safety and Quality Committee.

Dr. Kersey serves on the board of directors of the Johns Hopkins Aramco Healthcare, LLC (JHAH) joint venture based in Dhahran, Saudi Arabia, one of the world’s largest population health management initiatives.

Dr. Kersey’s international experience includes work with Sumitomo Biosciences in Japan and the World Bank in the former Soviet Union (the Republic of Georgia) as well as research fellowships focusing on the National Health Service in the United Kingdom and Sweden-based Telefon LM AB Ericsson’s market entry into China.

Dr. Kersey received his B.A. degree from Stanford University, his M.B.A. degree from the Harvard Business School and his M.D. degree from the Emory University School of Medicine.